#863

Nice with data across the evolutionary spectrum. And that this was in females.

Haven’t looked at the paper but want to note that median lifespan extension is often more related to healthspan extension than longevity!

(why ITP and other aging studies generally focus on what the impact is on maximum lifespan)

1 Like
#864

Nope, sorry, but I haven’t really looked at it.

Good point. It’s just a conference abstract so I’m afraid the data about the max lifespan hasn’t been published.

1 Like
#865

I’m no expert, but just logically thinking about it, less glucose floating around the body means less available for cancer cells to feed on. Surely that reduces the chance of a cancer taking hold.

2 Likes
#866

Yes, but what is interesting is that rates of new cancer and rates of deaths from cancer are divided by two among SGLT2is users compared to other anti-diabetic drugs. So it’s probably not glucose-related. SGLT2is only have a modest effect on glucose levels anyway.

7 Likes
#867

Wow, that is huge. Depending on the data, that could be one of the biggest reasons to consider SGLTi in healthy individuals

5 Likes
#868

With the current medications available, getting to 100-110 seems fairly realistic even for couch potatoes.

2 Likes
#869

Can you share more about this!

(Found some potentially different synthesis below)

—

Meta analysis does not seem to agree with meaningful reduction

Seventy-six trials encompassing 116,375 participants were selected. Overall risk of bias was low. SGLT2 inhibitors did not reduce/increase the overall risk of cancer (RR, 1.03; 95% confidence interval [CI], 0.96–1.10) and cancer mortality (RR, 0.99; 95% CI, 0.85–1.16). SGLT2 inhibitors likely result in little to no difference in the risk of breast (RR, 1.01; 95% CI 0.77–1.32) and bladder cancers (RR, 0.93; 95% CI 0.71–1.21). Trial sequential analysis provided evidence that the sample size was sufficient to avoid missing alternative results.

Specific cancers (MR studies):

For genetic evidence, genetically proxied SGLT2 inhibition reduced the risk of overall (odds ratio=0.56, 95%CI=0.38 to 0.82), advanced (OR=0.52, 95%CI=0.27 to 0.99) and early-onset (OR=0.27, 95%CI=0.11 to 0.72) prostate cancer.

In primary analysis, SGLT2 inhibition was associated with reduced risk of bladder cancer (OR: 0.98, 95% CI: 0.97-0.99) per unit lowering of HbA1c level. A protective association was also observed for prostate cancer with odds ratio = 0.31 (95% CI = 0.21-0.47). However, we did not discover a causal relationship between SGLT2 inhibition and kidney cancer (OR: 1.00, 95% CI: 0.99-1.00).

2 Likes
#870

Here divided by 5: Canagliflozin - Another Top Anti-aging Drug - #334 by adssx

Here cancer‐related mortality divided by 2: Canagliflozin - Another Top Anti-aging Drug - #390 by adssx

Here divided by 2: Canagliflozin - Another Top Anti-aging Drug - #861 by adssx

Also, even more here for dapagliflozin: Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials 2022

Our meta-analysis showed that SGLT-2 inhibitors were significantly associated with an overall reduced risk of cancer as compared to placebo (RR = 0.35, CI 0.33–0.37, P = 0.00) with a particular effectiveness for dapagliflozin and ertuglifozin (RR = 0.06, CI 0.06–0.07 and RR = 0.22, CI 0.18–0.26, respectively). Network Medicine approaches may advance the possible repurposing of these drugs in patients with concomitant diabetes and cancer.

All the above in diabetic patients. Might not translate to normoglycemic people.

6 Likes
#871

Here’s a more recent meta-analysis of clinical trials: Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis 2024

Compared to the placebo SGLT2 inhibitors did not significantly increase the overall incidence of cancer (RR 1.01; 95% CI 0.94–1.08; p = 0.82).
However, dapagliflozin did significantly reduce the risk of bladder cancer by 47% (RR 0.53; 95% CI 0.35–0.81; p = 0.003).
Dapagliflozin reduced the risk of respiratory cancer by 26% (RR 0.74; 95% CI 0.55–1.00; p = 0.05). SGLT2 inhibitors (particularly mediated by dapagliflozin and ertugliflozin but not statistically significant) were associated with a greater risk of renal cancer than the placebo (RR 1.39; 95% CI 1.04–1.87; p = 0.03).

Trials last about 1y. So, I think it’s normal not to see effects. The finding for renal cancer might be concerning but cohort studies do not corroborate it: Sodium–Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study 2022

Use of SGLT2 inhibitors, as compared with GLP-1 receptor agonists, was not associated with a statistically significant increase in risk of bladder cancer (adjusted HR 0.88 [95% CI 0.59–1.31]) or renal cancer (adjusted HR 1.09 [95% CI 0.73–1.63]) (Table 1). In additional analyses, the adjusted HR did not increase with time since cohort entry (Table 1). In several sensitivity analyses, including those with adjustment for additional variables such as smoking and glycated hemoglobin, the findings did not differ materially from those of the main analyses (Table 1).

Given that MR studies did not find much and that dapagliflozin seems to be an outlier (in both clinical trials and longitudinal studies), the potential positive effects might be off-target and might not be class effects.

5 Likes
#872

The SGLT1 vs 2 debate is still on: The SGLT2 inhibitor canagliflozin, but not dapagliflozin or empagliflozin, ameliorates vascular calcification in a mouse model of nephrocalcinosis 2024

One more potential mechanism: The effect of dapagliflozin on anemia in patients with CKD 2024

The use of dapagliflozin for eight months resulted in a significant elevation in hemoglobin levels in patients with CKD. Further studies can explore of better understanding of the effect and confirm the mechanisms that explain this finding. Elevation of hemoglobin with SGLT2is may be closely linked to the reduction of cardiovascular mortality and heart failure.

Association between sodium–glucose cotransporter-2 (SGLT2) inhibitors and macular degeneration in patients with diabetes: a nationwide population-based study in Taiwan 2024

Compared to non-SGLT2i cohort, patients who received SGLT2i had a significantly lower risk of MD (adjusted hazard ratio = 0.70, 95%CI = 0.66–0.75).
We found that SGLT2is has a strong protective effect against MD in patients with diabetes. SGLT2is may have benefits beyond glycemic control in patients with DR. However, additional clinical and experimental studies are required.

Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial 2024

Empagliflozin therapy, compared to placebo, reduced systolic/diastolic BPs (mean group difference in change from baseline to week 24; −5.9 [95% confidence interval (CI), −10.4 to −1.4] mmHg/−2.9 [95% CI, −6.2 to 0.4] mmHg) and MAP ( −3.8 [95% CI, −7.0 to −0.7] mmHg).

Newer Glucose-Lowering Drugs and Risk of Gout: A Network Meta-Analysis of Randomized Outcomes Trials 2024

Compared with placebo, SGLT2 inhibitors were significantly associated with decreased risk of gout (RR, 0.51; 95% CI, 0.29–0.91) while both GLP-1RAs and DPP-4 inhibitors have no significant effects on gout risk. There were no significant differences between SGLT2 inhibitors and GLP-1RAs (RR, 0.75; 95%CI, 0.31–1.82) and between GLP-1RAs and DPP-4 inhibitors (RR, 0.39; 95%CI, 0.14–1.10).

3 Likes
#873

After reading this entire thread, I am definitely considering starting empaglifozin asap.

Lots of evidence about lots of different benefits. Only fear about weight loss (I’m already very thin).

Is there any evidence of the effects on the gastro system, on the microbiota? (my Achilles’ heel)

2 Likes
#874

I’m not sure that the weight loss effect are universal and that they apply to people already thin (contrary to semaglutide for instance).

Some papers (I probably posted them in this thread) suggest that the effects of SGLT2i are off target via microbiota rebalancing. But that’s just an assumption at this stage.

1 Like
#875

I wanted some clarification on this topic, so I asked Dr. Oracle and here was his answer. Quite interesting and informative, IMO, so I figured I’d pass it along:

Vascular Calcification in Chronic Kidney Disease vs. Atherosclerosis

Differences in Pathogenesis

Vascular Calcification in Chronic Kidney Disease (CKD)

Occurs primarily in the medial layer of the arterial wall (medial calcification)

Involves transformation of vascular smooth muscle cells (VSMCs) into an osteoblast-like phenotype

Driven by dysregulated mineral metabolism, including elevated calcium, phosphate, and parathyroid hormone levels

Atherosclerotic Calcification

Occurs primarily in the intimal layer of the arterial wall (intimal calcification)

Associated with inflammatory processes and lipid deposition within the atherosclerotic plaque

Driven by traditional cardiovascular risk factors, such as dyslipidemia, hypertension, and diabetes

Clinical Implications

Both forms of vascular calcification are associated with increased cardiovascular morbidity and mortality.

In CKD patients, medial calcification contributes to increased arterial stiffness and left ventricular hypertrophy, leading to cardiovascular complications.

Atherosclerotic calcification is a marker of advanced atherosclerotic disease and increased risk of myocardial infarction and stroke.

Treatment Considerations

CKD-related Vascular Calcification

Strict control of mineral metabolism (calcium, phosphate, and parathyroid hormone levels)

Use of non-calcium-based phosphate binders (e.g., sevelamer, lanthanum carbonate)

Vitamin K supplementation (potential inhibition of vascular calcification)

Atherosclerotic Calcification

Management of traditional cardiovascular risk factors (lipid-lowering, blood pressure control, glycemic control)

Antiplatelet and anticoagulant therapy for secondary prevention

Caveats and Guidelines

There are no specific guidelines for the treatment of vascular calcification in CKD or atherosclerosis.

Treatment strategies are based on managing the underlying disease processes and risk factors.

Early detection and monitoring of vascular calcification through imaging techniques (e.g., computed tomography, ultrasound) are recommended in high-risk populations.

2 Likes
#876

If you’re worried about weight loss, there’s a simple solution. Eat more calories. For most, this is an enjoyable process. I’d love to eat more of my favourite foods without having to worry about adding weight. :slight_smile:

Although your grocery bill may go up and it is possible to overcompensate for the weight loss. :wink:

3 Likes
#877

If caloric restriction is associated with longevity, then too many calories would probably put me in the opposite direction. Anyway, I’ve tried to increase my calories a lot and I still can’t gain weight. I’m celiac, my digestion is poor and nutrient absorption is even worse.

1 Like
#878

Have you tried gluten free huel?

Oliver Zolman mentions it here:

2 Likes
#879

I Did not know. I’ll take a look, thanks.

#880

IMG_7492
IMG_74921179×1552 154 KB

Canagliflozin (Cana), can extend the median survival of genetically heterogeneous UM-HET3 male mice and improve central metabolic control via increases in hypothalamic insulin responsiveness in aged males, as well as reduced age-associated hypothalamic inflammation. We studied the long- and short-term effects of Cana on hypothalamic metabolic control in UM-HET3 mice. Starting the treatment from 7 months of age, we show that 4 weeks of Cana treatment significantly reduced body weight and fat mass in male but not female mice that was associated with enhanced glucose tolerance and insulin sensitivity observed by 12 months. Indirect calorimetry showed that Cana treatment increased energy expenditure in male, but not female mice, at 12 months of age. Long-term Cana treatment increased metabolic rates in both sexes, and markedly increasing formation of both orexigenic and anorexigenic projections to the paraventricular nucleus of the hypothalamus (PVH) mostly in females by 25 months. Hypothalamic RNA-sequencing analysis revealed increased sex-specific genes and signaling pathways related to insulin signaling, glycogen catabolic pathway, neuropeptide signaling, and mitochondrial function upregulated by Cana, with males showing a more pronounced and sustained effect on metabolic pathways at both age groups.

3 Likes
#881

Snake oil!..

1 Like
#882

Why? Seems quite good to me actually